CVE-2023-38848

CVE-2023-38848 is a high-severity vulnerability in Linecorp Line with a CVSS 3.x base score of 7.5. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low. The underlying weakness is classified as CWE-284.

Key facts

Description

An issue in rmc R Beauty CLINIC Line v.13.6.1 allows a remote attacker to obtain sensitive information via crafted GET request.

Frequently asked questions

What is CVE-2023-38848?
An issue in rmc R Beauty CLINIC Line v.13.6.1 allows a remote attacker to obtain sensitive information via crafted GET request.
How severe is CVE-2023-38848?
CVE-2023-38848 has a CVSS 3.x base score of 7.5, rated high severity. It is exploitable over network with low attack complexity, requires no privileges and no user interaction. Impact on confidentiality is high, integrity none, and availability none.
Is CVE-2023-38848 being actively exploited?
It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 1% (48th percentile), an estimate of the probability of exploitation in the next 30 days.
What products are affected by CVE-2023-38848?
CVE-2023-38848 affects Linecorp Line. See the affected-products list for the exact vulnerable versions.
How do I fix CVE-2023-38848?
Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround. Given its high severity, prioritise patching exposed systems.
When was CVE-2023-38848 published?
CVE-2023-38848 was published on 2023-10-25 and last updated on 2026-06-17.

References

Affected products (1)

More vulnerabilities in Linecorp Line

All CVEs affecting Linecorp Line →

Other CWE-284 (Improper Access Control) vulnerabilities

Browse all CWE-284 (Improper Access Control) vulnerabilities →